Skip to main content
Caplight Logo









Rapidemic

Rapidemic

Private
LeidenHealthcare & Life Scienceshttps://rapidemic.com/

Last Round

Grant

Sep 25, 2025

Total Funding Raised

$811,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Rapidemic is a diagnostic equipment company that develops ultrarapid, power-free molecular diagnostic tests for infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

molecular diagnosticspoint-of-care testingPOCTinfectious disease testingSTI testingrapid diagnostic testRDTpower-free diagnosticsdecentralized testingmedical devicebiotechnologylow-resource diagnosticslab-on-a-chipnucleic acid amplificationglobal health tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rapidemic Comparables

Compare Rapidemic with similar companies based on industry and business-model similarity.

Rapidemic comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ExGen Dx
88%
Fuse Diagnostics
82%
Selfdiagnostics
81%

Rapidemic Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 25, 2025
GrantJun 10, 2023
GrantJan 14, 2023
GrantJan 1, 2023
Pre SeedDec 13, 2021

Key People

Founding team and executive leadership

Violette Defourt

Founder & CEO

Founding Team

Peter Rahfeld

Chief Operating Officer

Executive Team

Rapidemic Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 399% MoM.

  • Feb 15, 2026

    Grew 44% QoQ from 9 to 13 employees.

Rapidemic Filings

Explore SEC and related filing metadata, where available.

Rapidemic filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Rapidemic's valuation, stock price, and market status.

Is Rapidemic a public or private company?

Rapidemic is a private company.

What is the current stock price of Rapidemic?

Rapidemic is a private company with no public stock price. No recent secondary market data is available.

How much is Rapidemic worth (valuation)?

Valuation information for Rapidemic is not publicly available.

Can I buy Rapidemic stock?

Rapidemic shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Rapidemic's last funding round?

Rapidemic's most recent funding round was Grant on September 25, 2025.

Who are the main investors in Rapidemic?

Key investors in Rapidemic include Netherlands Organization for Scientific Research, Bill & Melinda Gates Foundation, Graduate Entrepreneur, Women TechEU.

Will Rapidemic IPO soon?

No public IPO plans have been announced for Rapidemic.

How can I track Rapidemic secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Rapidemic's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLeiden
Employee Range14
Year Founded2021
Last FundingSep 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?